Tin tức & Cập nhật

Financial toxicity in prostate cancer means less spending on basic goods, leisure
Financial toxicity in prostate cancer means less spending on basic goods, leisure
29 Jul 2023

Patients with metastatic prostate cancer who report high financial toxicity tend to spend less on basic goods and leisure activity and use their savings to pay for care, according to the results of a cross-sectional study.

Financial toxicity in prostate cancer means less spending on basic goods, leisure
29 Jul 2023
Niraparib maintenance confers prolonged survival in advanced ovarian cancer
Niraparib maintenance confers prolonged survival in advanced ovarian cancer
27 Jul 2023
Cilta-cel a new Soc for lenalidomide-refractory MM?
Cilta-cel a new Soc for lenalidomide-refractory MM?
26 Jul 2023 bởiAudrey Abella

In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.

Cilta-cel a new Soc for lenalidomide-refractory MM?
26 Jul 2023
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
25 Jul 2023 bởiJairia Dela Cruz

Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.

SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
25 Jul 2023
Age, tumour size predict post-TACE complications in HCC patients
Age, tumour size predict post-TACE complications in HCC patients
21 Jul 2023 bởiStephen Padilla

In patients with hepatocellular carcinoma (HCC), most complications following transarterial chemoembolization (TACE) involve minor postembolization syndrome, reveals a study presented at EASL 2023. The incidence of major complications is high at 25 percent, with a 1.8-percent death rate.

Age, tumour size predict post-TACE complications in HCC patients
21 Jul 2023